Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib open-label trial of cAd3 Ebola vaccines in healthy adults in Uganda
PACTR201412000957310Phase 1Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2015
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 1, open-label trial of cAd3-EBO and cAd3-EBOV in Ebola virus disease (EVD) (2 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Safety, Tolerability and 1 more. Planned start Jan 2015; status: not yet recruiting.
02
Drugs
cAd3-EBOcAd3-EBOV
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on PACTR201412000957310.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR201412000957310.